- KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT
-
Compounds that function as kinase inhibitors are provided. The kinase inhibitors can have any structure of the formulae provided herein, such as shown for Compounds 1-4. A pharmaceutical composition can include: the compound of one of the embodiments; and
- -
-
Paragraph 0166-0168
(2021/03/05)
-
- Crystal packing: An examination of the packing of molecules approximately isosteric with 4,5-dichlorophthalic anhydride
-
The crystal structures of five 5,6-disubstituted benzofurazan 1-oxides are presented and compared with five previously reported structures: three polymorphs of 5,6-dichlorobenzofurazan 1-oxide plus 4,5-dichloro- and 4,5-dibromophthalic anhydride. All but one of these compounds pack with similar two-dimensional layers. The benzofurazan oxides all show disorder about a crystallographic twofold or pseudo-twofold axis. In addition, six complexes of phthalic anhydride and benzofurazan oxides are reported. With the packing in the complexes principally directed by the π complexing, the disorder, invariably found in the uncomplexed benzofurazan oxides, is diminished, and, in two cases, eliminated.
- Britton, Doyle,Noland, Wayland E.,Pinnow, Matthew J.,Young Jr., Victor G.
-
p. 1175 - 1192
(2007/10/03)
-
- Glutamate receptor antagonists
-
The present invention relates to compounds of with a base structure of formula 1 The compounds of formula I are shown to have activity as metabotropic glutamate receptor antagonists.
- -
-
-
- Cyclic guanidines. 17. Novel (N-substituted amino)imidazo[2,1-b]quinazolin-2-ones: Water-soluble platelet aggregation inhibitors
-
A series of novel 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one derivatives substituted with a secondary amino group has been prepared and tested for the activities of inhibiting platelet aggregation in rats in vitro and ex vivo. Most of the compounds
- Ishikawa,Saegusa,Inamura,Sakuma,Ashida
-
p. 1387 - 1393
(2007/10/02)
-